A Ventura County based biotech giant says it’s dropping its testing of a drug which it hoped would be an important new tool in fighting pancreatic cancer.
Amgen says it’s stopping its human testing of “Ganiturnab”, because a panel of researchers feel it isn’t meeting its goal of extending the lives of patients.
The drug was being used in conjunction with chemotherapy on pancreatic cancer patients. The company had been developing the drug with a Japanese company.
The drug was in Phase Three testing, which is typically the final round required for U.S. regulatory approval. Amgen is dropping both Phase Three, and Phase Two testing.